509 related articles for article (PubMed ID: 23702914)
1. Pathophysiology and management of primary immune thrombocytopenia.
Kashiwagi H; Tomiyama Y
Int J Hematol; 2013 Jul; 98(1):24-33. PubMed ID: 23702914
[TBL] [Abstract][Full Text] [Related]
2. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura.
Gernsheimer TB
Hematology Am Soc Hematol Educ Program; 2008; ():219-26. PubMed ID: 19074086
[TBL] [Abstract][Full Text] [Related]
3. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
4. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.
Stasi R; Evangelista ML; Stipa E; Buccisano F; Venditti A; Amadori S
Thromb Haemost; 2008 Jan; 99(1):4-13. PubMed ID: 18217129
[TBL] [Abstract][Full Text] [Related]
5. The biology of thrombopoietin and thrombopoietin receptor agonists.
Kuter DJ
Int J Hematol; 2013 Jul; 98(1):10-23. PubMed ID: 23821332
[TBL] [Abstract][Full Text] [Related]
6. [Recent progress in immune thrombocytopenia pathophysiology and treatment].
Kato H
Rinsho Ketsueki; 2023; 64(9):1106-1115. PubMed ID: 37899189
[TBL] [Abstract][Full Text] [Related]
7. The pathogenesis of chronic immune thrombocytopenic purpura.
McMillan R
Semin Hematol; 2007 Oct; 44(4 Suppl 5):S3-S11. PubMed ID: 18096470
[TBL] [Abstract][Full Text] [Related]
8. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.
Stasi R; Evangelista ML; Amadori S
Drugs; 2008; 68(7):901-12. PubMed ID: 18457458
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
Agnelli Giacchello J; Valeri F; Boccadoro M; Borchiellini A
Eur J Haematol; 2018 Mar; 100(3):304-307. PubMed ID: 29243329
[TBL] [Abstract][Full Text] [Related]
10. Positioning new treatments in the management of immune thrombocytopenia.
Arnold DM
Pediatr Blood Cancer; 2013; 60 Suppl 1(Suppl 1):S19-22. PubMed ID: 23109488
[TBL] [Abstract][Full Text] [Related]
11. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
12. Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview.
Vibor M; Rogulj IM; Ostojic SK
Cardiovasc Hematol Disord Drug Targets; 2017 Jul; 17(1):38-51. PubMed ID: 28034281
[TBL] [Abstract][Full Text] [Related]
13. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
Kuter DJ
Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
Kapur R; Aslam R; Speck ER; Rebetz JM; Semple JW
Platelets; 2020; 31(3):399-402. PubMed ID: 31146647
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists.
Pecci A
Int J Hematol; 2013 Jul; 98(1):34-47. PubMed ID: 23636669
[TBL] [Abstract][Full Text] [Related]
16. Guest editorial: Pathophysiology and management of thrombocytopenia: possible clinical application of TPO receptor agonists.
Tomiyama Y
Int J Hematol; 2013 Jul; 98(1):8-9. PubMed ID: 23793996
[No Abstract] [Full Text] [Related]
17. Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.
Yang F; Zong H; Li F; Luo S; Zhang X; Xu Y; Zhang X
Platelets; 2023 Dec; 34(1):2135694. PubMed ID: 36281771
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
[TBL] [Abstract][Full Text] [Related]
19. Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study.
Åkesson A; Bussel JB; Martin M; Blom AM; Klintman J; Ghanima W; Zetterberg E; Garabet L
Platelets; 2023 Dec; 34(1):2159019. PubMed ID: 36636835
[TBL] [Abstract][Full Text] [Related]
20. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro.
Chang M; Nakagawa PA; Williams SA; Schwartz MR; Imfeld KL; Buzby JS; Nugent DJ
Blood; 2003 Aug; 102(3):887-95. PubMed ID: 12676790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
